Tag: Gilead Sciences Inc
-
Sickle cell gene therapies offer new hope, but access remains a major challenge
FDA-approved gene therapies for sickle cell disease offer a chance to help patients, but factors including cost and access have slowed their use.
-
Bank of America is bullish on these top stocks ahead of earnings
Bank of America highlighted some of its best ideas heading into third-quarter earnings.
-
For the final 10% of cystic fibrosis patients, the breakthrough still hasn’t come
For the final 10% of cystic fibrosis patients who cannot benefit from breakthrough drugs, Emily’s Entourage is funding research to find treatments.
-
AstraZeneca CEO says Summit drug could drive next generation of cancer combinations after $2 billion investment
Pascal Soriot spoke exclusively with CNBC from the site of AstraZeneca’s new $1 billion R&D facility in Kendall Square in Cambridge, Massachusetts.
-
BioMarin reports five-year Pompe disease data showing durable motor function
BioMarin shared five-year data showing a combination therapy helped adults with late-onset Pompe disease maintain motor function.
-
One drug, many rare diseases. Inside the movement to make rare drug development more profitable
The Ladders to Cures Accelerator aims to develop treatments for multiple rare diseases through shared biological mechanisms.
-
NIH funding cuts delayed a promising childhood brain cancer trial. Patients lost time they didn’t have
A delayed clinical trial underscores the stakes of federal research funding cuts for children with DIPG, a deadly brain tumor with few treatment options.
-
Athletes with autism take center court at the US Open
Young athletes with autism were on the US Open courts with Love Serving Autism, using racquet sports to build confidence, connection and life skills.
-
A rare disease is taking his vision. A gene therapy could help — if he can get it
A well-connected family’s fight to access a potential treatment for their son highlights the barriers most rare disease patients struggle to overcome.
-
AstraZeneca’s COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
The full data reinforces hopes that the drug could be a breakthrough COPD treatment and reach AstraZeneca’s peak annual sales forecast of more than $5 billion.
Latest News
Stay Connected
Categories
BBC News CNA CNBC CNN International Deutsche Welle (DW) Euronews France 24 General Global & European Specialized & Regional
Tags
amp Artificial intelligence Asia Breaking News: Business Breaking News: Markets Breaking News: Politics Breaking News: Technology Business business news cent china cup Donald J. Trump Donald Trump economy European Union fast football France germany india Investment strategy iran Iran war markets People per politics return russia S&P 500 Index said Singapore spain Sport Stock markets technology trump ukraine United States US-Israel attack on Iran 2026 video War in Ukraine World World Cup 2026
About the Author
AF themes
Easy WordPress Websites Builder: Versatile Demos for Blogs, News, eCommerce and More – One-Click Import, No Coding! 1000+ Ready-made Templates for Stunning Newspaper, Magazine, Blog, and Publishing Websites.
Search the Archives
Access over the years of investigative journalism and breaking reports
You May Have Missed
